Barbara Eichhorst

Barbara Eichhorst

UNVERIFIED PROFILE

Are you Barbara Eichhorst?   Register this Author

Register author
Barbara Eichhorst

Barbara Eichhorst

Publications by authors named "Barbara Eichhorst"

Are you Barbara Eichhorst?   Register this Author

76Publications

1988Reads

8Profile Views

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

N Engl J Med 2019 06 4;380(23):2225-2236. Epub 2019 Jun 4.

From Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital Cologne and University of Cologne (K.F., O.A.-S., J.B., A.-M.F., S. Robrecht, B.E., K.-A.K., M.H.), the Oncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital (V.G.), CECAD (Center of Excellence on Cellular Stress Responses in Aging-Associated Diseases) (M.H.), Center for Molecular Medicine Cologne (M.H.), Cologne, Department III of Internal Medicine, University Hospital Rostock, Rostock (S.B.), Department III of Internal Medicine, Ulm University, Ulm (E.T., S.S.), the Departments of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases, and Tropical Medicine, Klinikum Schwabing, Munich (C.-M.W.), Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel (M.R.), and the Department of Hematology, Oncology, and Rheumatology, Saarland University Medical School, Homburg (S.S.) - all in Germany; Roche Products, Welwyn Garden City, United Kingdom (M.T., M.D., S.W., K.H.); Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod, Russia (O.S.); the Division of Onco-Hematology, Santa Maria Terni Hospital, University of Perugia, Perugia, Italy (A.M.L.); the Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J.P.-I.); the Haematology Department, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia (S.O.); First Internal Department, Multiprofile Hospital for Active Treatment Hristo Botev, Vratsa, Bulgaria (L.S.); the Hematology Department, Clinique Victor Hugo, Le Mans, France (K.L.D.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (L.M.F.); the Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen (C.U.N.); Wellington Blood and Cancer Centre, Capital and Coast District Health Board, and Malaghan Institute of Medical Research, Wellington, New Zealand (R.W.); Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada (S. Robinson); Moores Cancer Center, University of California San Diego, San Diego (T.J.K.), and Genentech, South San Francisco (M.M.) - both in California; AbbVie, North Chicago, IL (R.H.); and the Department of Immunology, Laboratory Medical Immunology, Erasmus MC, Rotterdam, the Netherlands (A.W.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1815281DOI Listing
June 2019

CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.

Leukemia 2019 05 19;33(5):1161-1172. Epub 2018 Dec 19.

Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, CECAD Cluster of Excellence at the University of Cologne, Clinical Research Unit (KFO) 286, German CLL Study Group, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0313-8DOI Listing
May 2019

Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.

Leukemia 2019 May 14. Epub 2019 May 14.

Department of Medicine V, University Hospital Heidelberg, Department of Molecular Therapy in Haematology & Oncology, NCT/DKFZ, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0475-zDOI Listing
May 2019

The Treatment of Chronic Lymphatic Leukemia.

Dtsch Arztebl Int 2019 01;116(4):41-46

Department of Internal Medicine I - Oncology, Hematology, Clinical Infectiology, Clinical Immunology, Hemostaseology, Internal Intensive Care; University Hospital Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3238/arztebl.2019.0041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6415618PMC
January 2019

Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia.

Br J Haematol 2018 12 21;183(5):727-735. Epub 2018 Nov 21.

Department I of Internal Medicine and Centre of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15604DOI Listing
December 2018

Management of unfit elderly patients with chronic lymphocytic leukemia.

Eur J Intern Med 2018 12;58:7-13

German CLL Study Group (GCLLSG), Dept. I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany; Oncogeriatric Unit, Dept. of Geriatric Medicine, St. Marien Hospital, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejim.2018.02.001DOI Listing
December 2018

[Individualized Treatment of Chronic Lymphocytic Leukemia (CLL)].

Dtsch Med Wochenschr 2018 09 10;143(18):1318-1324. Epub 2018 Sep 10.

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/a-0550-2286
Publisher Site
http://dx.doi.org/10.1055/a-0550-2286DOI Listing
September 2018

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

J Clin Oncol 2018 07 1;36(19):1973-1980. Epub 2018 May 1.

Stephan Stilgenbauer and Johannes Bloehdorn, Ulm University, Ulm; Stephan Stilgenbauer, Klinik für Innere Medizin I, Universitätsklinikum des Saarlandes, Homburg; Barbara Eichhorst and Michael Hallek, Universitätsklinikum Köln, Köln; Johannes Schetelig, University Hospital, Technische Universität Dresden, Dresden; Clemens-Martin Wendtner, Klinikum Schwabing, Munich; Sebastian Böttcher, University Hospital of Schleswig-Holstein, Kiel, Germany; Peter Hillmen and Talha Munir, St James's University Hospital, Leeds; Anna Schuh, University of Oxford; Anna Schuh, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom; John F. Seymour, Peter MacCallum Cancer Centre; John F. Seymour, University of Melbourne; Andrew W. Roberts, Royal Melbourne Hospital, Parkville, Victoria; Stephen P. Mulligan, Royal North Shore Hospital, St Leonards, New South Wales, Australia; Steven Coutre, Stanford University Medical Center, Stanford, CA; Wojciech Jurczak, Jagiellonian University, Kraków, Poland; Sarit Assouline, McGill University, Montreal, Quebec, Canada; Matthew S. Davids, Dana-Farber Cancer Institute, Boston, MA; Lang Zhou, Ahmed Hamed Salem, Monali Desai, Brenda Chyla, Jennifer Arzt, Su Young Kim, Maria Verdugo, and Gary Gordon, AbbVie, North Chicago, IL; Ahmed Hamed Salem, Ain Shams University, Cairo, Egypt; and William G. Wierda, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.6840DOI Listing
July 2018

Chronic lymphocytic leukaemia.

Lancet 2018 04 21;391(10129):1524-1537. Epub 2018 Feb 21.

Department of Internal Medicine, Center of Integrated Oncology Köln Bonn, University Hospital of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)30422-7DOI Listing
April 2018

CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.

Future Oncol 2018 Mar 21;14(6):499-513. Epub 2018 Feb 21.

Department I of Internal Medicine & Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0442DOI Listing
March 2018

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

N Engl J Med 2018 Mar;378(12):1107-1120

From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) - all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) - both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne-Bonn, Cologne, Germany (B.E.); St. James's University Hospital, Leeds (P.H.), and F. Hoffmann-La Roche, Welwyn Garden City (M.B., K.H.) - both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) - all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1713976DOI Listing
March 2018

Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.

Eur J Haematol 2017 Mar 1;98(3):254-262. Epub 2016 Dec 1.

Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study group, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12825DOI Listing
March 2017

Targeted Therapy of CLL.

Oncol Res Treat 2016 15;39(12):768-778. Epub 2016 Nov 15.

Department I of Internal Medicine, German CLL Study Group, Center for Integrated Oncology Cologne-Bonn, University Hospital of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000452786DOI Listing
March 2017

FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia.

Leuk Lymphoma 2017 02 29;58(2):399-407. Epub 2016 Jun 29.

a Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn , University Hospital of Cologne , Cologne , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2016.1190966DOI Listing
February 2017

Economic evaluation of chronic lymphocytic leukemia from a hospital management perspective.

Eur J Haematol 2017 Feb 1;98(2):169-176. Epub 2016 Nov 1.

Department I of Internal Medicine, Center for Integrated Oncology Cologne, University Hospital of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12817DOI Listing
February 2017

Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group.

Leuk Lymphoma 2016 13;57(4):789-96. Epub 2015 Oct 13.

a German CLL Study Group, Department I of Internal Medicine , Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne , Cologne , Germany .

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.3109/10428194.2015.10
Publisher Site
http://dx.doi.org/10.3109/10428194.2015.1091933DOI Listing
December 2016

State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia.

Oncol Res Treat 2016 22;39(1-2):25-32. Epub 2016 Jan 22.

Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn and German CLL Study Group, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000443903DOI Listing
December 2016

Prognostication of chronic lymphocytic leukemia in the era of new agents.

Hematology Am Soc Hematol Educ Program 2016 Dec;2016(1):149-155

Department I for Internal Medicine and Centre of Integrated Oncology, and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2016.1.149DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142472PMC
December 2016

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.

J Clin Oncol 2016 11;34(31):3758-3765

Gabor Kovacs, Sandra Robrecht, Anna Maria Fink, Jasmin Bahlo, Paula Cramer, Julia von Tresckow, Christian Maurer, Petra Langerbeins, Kirsten Fischer, Michael Hallek, and Barbara Eichhorst, University of Cologne and Center of Integrated Oncology Cologne/Bonn, Cologne; Matthias Ritgen, Michael Kneba, and Sebastian Böttcher, University of Schleswig-Holstein, Lubeck; Hartmut Döhner and Stephan Stilgenbauer, University of Ulm, Ulm; Wolfram Klapper, University of Kiel, Kiel; Clemens-Martin Wendtner, Klinikum Schwabing, Munich, Germany; and Günter Fingerle-Rowson, F. Hoffmann La-Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.1305DOI Listing
November 2016

New treatment approaches in CLL: Challenges and opportunities in the elderly.

J Geriatr Oncol 2016 09 1;7(5):375-82. Epub 2016 Aug 1.

German CLL Study Group (GCLLSG), Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne, Germany; Department of Geriatric Medicine, St. Marien Hospital, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2016.07.007DOI Listing
September 2016

Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota.

Oncoimmunology 2016 Jun 22;5(6):e1150399. Epub 2016 Apr 22.

1st Department of Internal Medicine and Center for Integrated Oncology CIO Köln/Bonn, University Hospital of Cologne, Cologne, Germany; German Center for Infection Research (DZIF), Partner site Bonn-Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2016.1150399DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938364PMC
June 2016

Dose-reduced fludarabine, cyclophosphamide and rituximab (FCR) in older patients with chronic lymphocytic leukemia: does one size fit all?

Leuk Lymphoma 2016 May;57(5):987-90

a Department I of Internal Medicine , Center of Integrated Oncology Cologne-Bonn and German CLL Study Group, University of Cologne , Cologne , Germany ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2016.1164858DOI Listing
May 2016

Individualizing treatment decisions for older adults with hematologic malignancies.

Am Soc Clin Oncol Educ Book 2013 :208-19

From the Comprehensive Cancer Center of Wake Forest University, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC; Department of Medicine, Division of Hematologic Malignancies and Cell Therapy, Duke University Medical Center, Durham, NC; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy; Department I of Internal Medicine and Center of Integrated Oncology Köln Bonn, University of Cologne, Köln, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EdBook_AM.2013.33.208DOI Listing
April 2016

The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression.

Future Oncol 2015 ;11(13):1895-903

Department I of Internal Medicine, Center of Integrated Oncology (CIO), & CECAD - Cluster of Excellence 'Cellular Stress Responses in Aging-Associated Diseases,' University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.15.95DOI Listing
April 2016

Initial therapy of chronic lymphocytic leukemia.

Semin Oncol 2016 Apr 9;43(2):241-50. Epub 2016 Feb 9.

Department I for Internal Medicine and Center of Integrated Oncology, University of Cologne, Cologne, Germany; CECAD-Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2016.02.005DOI Listing
April 2016

Current strategies to create tailored and risk-adapted therapies for CLL patients.

Best Pract Res Clin Haematol 2016 03 12;29(1):111-121. Epub 2016 Aug 12.

Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University Hospital, Cologne, Germany; German CLL Study Group, University Hospital Cologne, Cologne, Germany; CECAD, University Hospital Cologne, Cologne Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2016.08.010DOI Listing
March 2016

Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG).

Eur J Haematol 2016 Jan 6;96(1):9-18. Epub 2015 Nov 6.

Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn and German CLL Study Group, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12678DOI Listing
January 2016

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Blood 2016 Jan 20;127(2):208-15. Epub 2015 Oct 20.

Department I for Internal Medicine and Center of Integrated Oncology, University of Cologne, Cologne, Germany; Cluster of Excellence Cellular Stress Responses in Aging Associated Diseases, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-06-651125DOI Listing
January 2016

Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia.

Leuk Lymphoma 2015 Jun 20;56(6):1585-92. Epub 2014 Nov 20.

German CLL Study Group, Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne , Cologne , Germany.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.3109/10428194.2014.96
Publisher Site
http://dx.doi.org/10.3109/10428194.2014.963077DOI Listing
June 2015

Second cancers in chronic lymphocytic leukemia: growing importance in the era of improved treatment outcomes.

Leuk Lymphoma 2015 Jun 12;56(6):1575-6. Epub 2015 May 12.

Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne , Cologne , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1030643DOI Listing
June 2015

Emerging therapies for refractory chronic lymphocytic leukemia.

Leuk Lymphoma 2015 Feb 27;56(2):285-92. Epub 2014 Jun 27.

Department I of Internal Medicine, Center of Integrated Oncology (CIO), CECAD (Cluster of Excellence in Cellular Stress Responses in Aging-associated Diseases) and German CLL Study Group (DCLLSG), University of Cologne , Cologne , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.917641DOI Listing
February 2015

Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.

Am J Hematol 2014 Dec 26;89(12):E239-43. Epub 2014 Sep 26.

Department I of Internal Medicine, Center of Integrated Oncology (CIO), and CECAD-Cluster of Excellence "Cellular Stress Responses in Aging-Associated Diseases," University of Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23841DOI Listing
December 2014

Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials.

Haematologica 2014 Jun 28;99(6):1095-100. Epub 2014 Feb 28.

Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University of Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2013.096792DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040914PMC
June 2014

Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

N Engl J Med 2014 Mar 8;370(12):1101-10. Epub 2014 Jan 8.

From the German CLL Study Group, Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne (V.G., K.F., A.E., B.E., C.M.W., K.-A.K., M.H.), the Department for Geriatric Medicine and Research, St. Marien Hospital and University of Cologne, Cologne (V.G.), Institute of Medical Statistics and Epidemiology, Technical University Munich, Munich (R.B.), Klinikum Schwabing, Munich (C.M.W.), private oncology practice, Dresden (T.I.), Medical Department II, University of Schleswig-Holstein, City Hospital Kiel, Kiel (M.R., M.K.), the Department of Internal Medicine III, Ulm University, Ulm (S.S., H.D.), and Cluster of Excellence "Cellular Stress Responses in Aging-Associated Diseases" (CECAD), University of Cologne, Cologne (M.H.) - all in Germany; Penza Regional Oncology Dispensary, Penza (T.C.), and Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod (O.S.) - both in Russia; Servicio De Hematologia, Hospital Universitario 12 De Octubre, Madrid (J.S.); Hôpital Haut Lévêque, Bordeaux, Pessac, France (M.-S.D.); the Department of Haematology, Monash Medical Centre, Clayton, Australia (S.O.); University of Calgary, Calgary, AB, Canada (C.J.O.); the Department of Immunology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands (A.W.L.); F. Hoffmann-La Roche, Basel, Switzerland (E.A.); F. Hoffmann-La Roche, Welwyn, United Kingdom (K.H.); and Genentech, South San Francisco, CA (M.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1313984DOI Listing
March 2014

Extramedullary manifestations of chronic lymphocytic leukaemia are not unusual.

Leuk Res 2014 Mar 1;38(3):284-5. Epub 2013 Dec 1.

Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2013.11.015DOI Listing
March 2014

Frontline therapy for chronic lymphocytic leukemia patients.

Clin Adv Hematol Oncol 2009 Oct;7(10):638-41

University Hospital, University of Cologne, Germany.

View Article

Download full-text PDF

Source
October 2009

Treatment of elderly patients with chronic lymphocytic leukemia.

Leuk Lymphoma 2009 Feb;50(2):171-8

Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190802688517DOI Listing
February 2009

Use of alemtuzumab and rituximab consolidation in CLL: Pros and cons.

Curr Hematol Malig Rep 2009 Jan;4(1):43-6

Department I of Internal Medicine, University of Cologne, Kerpener Strasse 62, 50937, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-009-0006-5DOI Listing
January 2009

Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL).

Best Pract Res Clin Haematol 2007 Sep;20(3):469-77

Klinik I für Innere Medizin, Universität zu Köln, Kerpenerstr. 62, D-50924 Köln, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2007.02.002DOI Listing
September 2007

Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia.

Hematol J 2004 ;5 Suppl 1:S20-30

Klinik I für Innere Medizin, Universität zu Köln, Köln, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.thj.6200388DOI Listing
December 2004